CC-Header

Conference Correspondent™ provides on-site daily coverage of key sessions at particular scientific meetings. Conference Correspondent™ takes healthcare providers to meetings they cannot attend live, and your sponsorship helps create awareness for your brand or therapeutic area.

View All Conference Highlights

WCLC 2025 - Non-Small Cell Lung Cancer

Zongertinib in HER2-Mutant NSCLC With Brain Metastases: Findings From the Beamion LUNG-1 Trial
By Stephanie McDonald, FNP-BC, AOCNP
WCLC 2025 - Non-Small Cell Lung Cancer
World Conference on Lung Cancer (WCLC)
Clinical Outcomes in HER2-Mutant NSCLC Treated With Sevabertinib: Insights From the SOHO-01 Phase 1/2 Trial
By Stephanie McDonald, FNP-BC, AOCNP
WCLC 2025 - Non-Small Cell Lung Cancer
World Conference on Lung Cancer (WCLC)

VIEW FULL COVERAGE

ASCO 2025 - Non-Small Cell Lung Cancer

Patient-Reported Outcomes Highlight Favorable Tolerability of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial
By Beth Sandy, MSN, CRNP, FAPO
ASCO 2025 - Non-Small Cell Lung Cancer
American Society of Clinical Oncology (ASCO)
Safety and Efficacy of Sevabertinib (BAY 2927088) in HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Phase I/II SOHO-01 Trial
By Beth Sandy, MSN, CRNP, FAPO
ASCO 2025 - Non-Small Cell Lung Cancer
American Society of Clinical Oncology (ASCO)

VIEW FULL COVERAGE

AACR 2025 - Non–Small Cell Lung Cancer

Promising Efficacy and Manageable Safety of Zongertinib in HER2-Mutant NSCLC: Insights From the Beamion LUNG-1 Trial
By Martin F. Dietrich, MD, PhD
AACR 2025 - Non–Small Cell Lung Cancer
American Association for Cancer Research (AACR)
Efficacy and Safety of Tiragolumab Plus Atezolizumab in PD-L1–High NSCLC: Insights From the SKYSCRAPER-01 Trial
By Martin F. Dietrich, MD, PhD
AACR 2025 - Non–Small Cell Lung Cancer
American Association for Cancer Research (AACR)

VIEW FULL COVERAGE

ASCO 2025 - Breast Cancer Faculty Commentary

Safety of Imlunestrant in ER-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial Results
By Hope S. Rugo, MD, FASCO
ASCO 2025 - Breast Cancer Faculty Commentary
American Society of Clinical Oncology (ASCO)
Promising Results for Elacestrant Combinations in ER-Positive, HER2-Negative Metastatic Breast Cancer: ELEVATE Trial Findings
By Hope S. Rugo, MD, FASCO
ASCO 2025 - Breast Cancer Faculty Commentary
American Society of Clinical Oncology (ASCO)

VIEW FULL COVERAGE

ASCO 2025 - Wrap Up: Triple-Negative Breast Cancer

Phase 2 Study of BEBT-209 Plus Gemcitabine and Carboplatin in Metastatic TNBC
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
American Society of Clinical Oncology (ASCO)
NeoSTAR Arm A2: Evaluating Sacituzumab Govitecan and Pembrolizumab as Neoadjuvant Therapy for Early-Stage TNBC
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
American Society of Clinical Oncology (ASCO)

VIEW FULL COVERAGE


© Amplity, Inc. All Rights Reserved. Privacy Policy